Qiagen Partners with Nvidia to Enhance Drug Discovery Efficiency
Qiagen (QGEN) announced at the 2026 BIO-IT World Conference & Expo in Boston that the Qiagen Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating Nvidia (NVDA) accelerated computing and the Nvidia BioNeMo platform to help researchers use AI more effectively in drug discovery. The integration is designed to help pharmaceutical and biotechnology researchers better understand disease biology, identify promising therapeutic targets and uncover biomarkers that can support faster and more effective development of new medicines. "QIAGEN Digital Insights has spent more than 25 years building the biomedical knowledge foundation that researchers rely on to interpret complex biology," said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. "Through this collaboration with NVIDIA, we can accelerate the impact of that knowledge by combining it with advanced AI to help customers improve critical steps in drug discovery, from target identification to biomarker research and hypothesis generation."
